Literature DB >> 15276472

Calcineurin-NFAT signaling regulates the cardiac hypertrophic response in coordination with the MAPKs.

Jeffery D Molkentin1.   

Abstract

Prolonged cardiac hypertrophy of pathologic etiology is associated with arrhythmia, sudden death, decompensation, and dilated cardiomyopathy. In an attempt to understand the mechanisms that underlie the hypertrophic response, extensive investigation has centered on a characterization of the molecular pathways that initiate or maintain the pathologic growth of individual cardiac myocytes. While a large number of signal transduction cascades have been identified as critical regulators of cardiac hypertrophy, here the scientific evidence implicating the protein phosphatase calcineurin (PP2B) and the mitogen-activated protein kinases (MAPK) as co-regulators of reactive hypertrophy will be discussed. Gain- and loss-of-function studies in genetically altered mice and in cultured cardiomyocytes have demonstrated the necessity and sufficiency of calcineurin to regulate pathologic cardiac hypertrophy. However, using similar approaches, the hypertrophic regulatory role attributed to various branches of the MAPK signaling pathway has been less conclusive, although a loose consensus suggests that the c-Jun N-terminal kinases (JNK) and p38 kinases function as mediators of dilated cardiomyopathy, while extracellular signal-regulated kinases (ERKs) function as regulators of hypertrophy. More recently, the actions of calcineurin and MAPK signaling pathways have been shown to be co-dependent such that unitary activation of calcineurin in myocytes leads to up-regulation in ERK and JNK signaling, but down-regulation in p38 signaling. Conversely, unitary activation of JNK or p38 in cardiac myocytes leads to down-regulation of calcineurin effectiveness by directly antagonizing nuclear factor of activated T cells (NFAT) nuclear occupancy. Thus, an emerging paradigm suggests that calcineurin-NFAT and MAPK signaling pathways are inter-dependent and together orchestrate the cardiac hypertrophic response. Copryright 2004 European Society of Cardiology

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15276472     DOI: 10.1016/j.cardiores.2004.01.021

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  172 in total

1.  Regulator of G-protein signalling 5 protects against atherosclerosis in apolipoprotein E-deficient mice.

Authors:  Wen-Lin Cheng; Pi-Xiao Wang; Tao Wang; Yan Zhang; Cheng Du; Hongliang Li; Yong Ji
Journal:  Br J Pharmacol       Date:  2015-01-12       Impact factor: 8.739

2.  O-GlcNAc signaling is essential for NFAT-mediated transcriptional reprogramming during cardiomyocyte hypertrophy.

Authors:  Heberty T Facundo; Robert E Brainard; Lewis J Watson; Gladys A Ngoh; Tariq Hamid; Sumanth D Prabhu; Steven P Jones
Journal:  Am J Physiol Heart Circ Physiol       Date:  2012-03-09       Impact factor: 4.733

3.  GnRH regulation of Jun and Atf3 requires calcium, calcineurin, and NFAT.

Authors:  April K Binder; Jean C Grammer; Maria K Herndon; Julie D Stanton; John H Nilson
Journal:  Mol Endocrinol       Date:  2012-03-22

4.  FGF23 induces left ventricular hypertrophy.

Authors:  Christian Faul; Ansel P Amaral; Behzad Oskouei; Ming-Chang Hu; Alexis Sloan; Tamara Isakova; Orlando M Gutiérrez; Robier Aguillon-Prada; Joy Lincoln; Joshua M Hare; Peter Mundel; Azorides Morales; Julia Scialla; Michael Fischer; Elsayed Z Soliman; Jing Chen; Alan S Go; Sylvia E Rosas; Lisa Nessel; Raymond R Townsend; Harold I Feldman; Martin St John Sutton; Akinlolu Ojo; Crystal Gadegbeku; Giovana Seno Di Marco; Stefan Reuter; Dominik Kentrup; Klaus Tiemann; Marcus Brand; Joseph A Hill; Orson W Moe; Makoto Kuro-O; John W Kusek; Martin G Keane; Myles Wolf
Journal:  J Clin Invest       Date:  2011-10-10       Impact factor: 14.808

Review 5.  Mitogen-activated protein kinase signaling in the heart: angels versus demons in a heart-breaking tale.

Authors:  Beth A Rose; Thomas Force; Yibin Wang
Journal:  Physiol Rev       Date:  2010-10       Impact factor: 37.312

6.  Tumor suppressor A20 protects against cardiac hypertrophy and fibrosis by blocking transforming growth factor-beta-activated kinase 1-dependent signaling.

Authors:  He Huang; Qi-Zhu Tang; Ai-Bing Wang; Manyin Chen; Ling Yan; Chen Liu; Hong Jiang; Qinglin Yang; Zhou-Yan Bian; Xue Bai; Li-Hua Zhu; Lang Wang; Hongliang Li
Journal:  Hypertension       Date:  2010-06-28       Impact factor: 10.190

Review 7.  Transcriptional mechanisms regulating Ca(2+) homeostasis.

Authors:  Michael F Ritchie; Yandong Zhou; Jonathan Soboloff
Journal:  Cell Calcium       Date:  2010-11-13       Impact factor: 6.817

8.  Regulator of G protein signaling 5 protects against cardiac hypertrophy and fibrosis during biomechanical stress of pressure overload.

Authors:  Hongliang Li; Chengwei He; Jinhua Feng; Yan Zhang; Qizhu Tang; Zhouyan Bian; Xue Bai; Heng Zhou; Hong Jiang; Scott P Heximer; Mu Qin; He Huang; Peter P Liu; Congxin Huang
Journal:  Proc Natl Acad Sci U S A       Date:  2010-07-19       Impact factor: 11.205

Review 9.  Atrophied cardiomyocytes and their potential for rescue and recovery of ventricular function.

Authors:  Mark R Heckle; David M Flatt; Yao Sun; Salvatore Mancarella; Tony N Marion; Ivan C Gerling; Karl T Weber
Journal:  Heart Fail Rev       Date:  2016-03       Impact factor: 4.214

Review 10.  Protein kinase cascades in the regulation of cardiac hypertrophy.

Authors:  Gerald W Dorn; Thomas Force
Journal:  J Clin Invest       Date:  2005-03       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.